Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Joshua Schrecker"'
Autor:
Randy E. David, Kelsy Gibson Ferrara, Joshua Schrecker, David Paculdo, Steven Johnson, Rhonda Bentley-Lewis, Rebecca Heltsley, John W. Peabody
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background Clinical management of patients with chronic cardiometabolic disease is complicated by polypharmacy. Consequently, when patients clinically deteriorate, physicians are challenged to distinguish both medication nonadherence and dru
Externí odkaz:
https://doaj.org/article/fe40f4cc81ec467da715f599fe3c6ba3
Autor:
John W Peabody, Divya Ganesan, Czarlota Valdenor, David Paculdo, Joshua Schrecker, Christopher Westerfield, Rebecca Heltsley
Publikováno v:
BMC Primary Care, Vol 24, Iss 1, Pp 1-10 (2023)
Abstract Background Disentangling nonadherence (NA), drug-drug interactions (DDIs), and disease progression from each other is an important clinical challenge for providers caring for patients with cardiometabolic diseases. NAs and DDIs are both ubiq
Externí odkaz:
https://doaj.org/article/9565fe0cb7844aa89f460d1aade8a527
Publikováno v:
PLoS ONE, Vol 17, Iss 10, p e0275150 (2022)
SARS-CoV-2, the virus that causes COVID-19, has many variants capable of rapid transmission causing serious illness. Timely surveillance of new variants is essential for an effective public health response. Ensuring availability and access to diagnos
Externí odkaz:
https://doaj.org/article/1b2bf6130f7c4f48ba8a49d96d144f36
Publikováno v:
Drugs - Real World Outcomes, Vol 5, Iss 4, Pp 217-224 (2018)
Abstract Background and Objective Aegis Sciences Corporation developed a test (InterACT Rx™) that objectively and definitively identifies substances known to interact with drug–drug interaction-prone medications commonly prescribed in the treatme
Externí odkaz:
https://doaj.org/article/cd775ac6ef0549a595ee23a05d7b722b
Autor:
John Peabody, Joshua Schrecker, Rebecca Heltsley, David Paculdo, Enrico de Belen, Diana Tamondong-Lachica, M. Czarina Acelajado, Othman Ouenes, Trina Kennedy, Elaine Jeter
Publikováno v:
Diagnostics, Vol 11, Iss 7, p 1266 (2021)
Drug–drug interactions (DDIs) are a serious problem in the healthcare system, leading to excess healthcare utilization and costs. We conducted a second prospective randomized, controlled trial to further establish the real-world clinical utility of
Externí odkaz:
https://doaj.org/article/fe976fcbc5db40b4bf348af7e989da2d
Autor:
Czarlota Valdenor, Divya Ganesan, David Paculdo, Joshua Schrecker, Rebecca Heltsley, Christopher Westerfield, John W. Peabody
Publikováno v:
International Journal of Clinical Practice. 2022:1-8
Background. Medication nonadherence in patients with chronic diseases is common, costly, and often underdiagnosed. In the United States, approximately 40–50% of patients with cardiometabolic conditions are not adherent to long-term medications. Dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aed788af57c62968c5bbce429e0c2927
https://doi.org/10.1155/2022/6450641
https://doi.org/10.1155/2022/6450641
Autor:
Cyndi Clark, Tanya Singh, Joshua Schrecker, Liang Feng, Joel Galanter, Amy Shah, Renae Smith-Ray, Matthew Hardison, Michael Taitel
UNSTRUCTURED Background: Genomic sequencing of SARS-CoV-2 positive specimens has been critical in detecting and tracking variants of concern. Methods: We analyzed a recent cohort of SARS-CoV-2-positive specimens collected from patients in over 5,000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ebfc6d668e76b253a386b62ed22e3e3
https://doi.org/10.2196/preprints.35060
https://doi.org/10.2196/preprints.35060
Autor:
Alec Vest, Holly Houdeshell, Cyndi Clark, Vikram Ghorpade, Rob Case, Joshua Schrecker, Matthew Hardison
Publikováno v:
Genetics in Medicine. 24:S208-S209
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54ffe3620bd1a4359f844365df356b20
https://doi.org/10.1016/j.gim.2022.01.368
https://doi.org/10.1016/j.gim.2022.01.368
Publikováno v:
Drugs-Real World Outcomes, Vol 5, Iss 4, Pp 217-224 (2018)
Drugs-Real World Outcomes
Drugs-Real World Outcomes
Background and Objective Aegis Sciences Corporation developed a test (InterACT Rx™) that objectively and definitively identifies substances known to interact with drug–drug interaction-prone medications commonly prescribed in the treatment of chr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93dfafbe1bfaa6f49a05e69db13bcea3
https://doi.org/10.1007/s40801-018-0143-z
https://doi.org/10.1007/s40801-018-0143-z
Autor:
David Paculdo, John W. Peabody, Elaine Jeter, Cheryl Hild, Mary Tran, Maria Czarina Acelajado, Joshua Schrecker, Tim Robert
Publikováno v:
Journal of Clinical Medicine Research
Background: Drug-drug interactions (DDIs) are ubiquitous, harmful and a leading cause of morbidity and mortality. With an aging population, growth in polypharmacy, widespread use of supplements, and the rising opioid abuse epidemic, primary care phys
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e126de52057445d4ca5a02938cdcfab9
https://doi.org/10.14740/jocmr3557w
https://doi.org/10.14740/jocmr3557w